Declaration of Voting Results & Voting Rights Announcements • May 7, 2020
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer

IBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on May 6, 2020.
In its notification, S.R.I.W. has notified, that following an introduction of additional notification thresholds in the articles of association of IBA, its total holding in IBA has crossed upwards the 1 % threshold on April 30, 2020.
In details, on April 30, 2020, S.R.I.W. owned 715.491 IBA shares conferring 715.491 voting rights, or 1.88% of the total shares with voting rights issued by IBA (38,085,047).
Press release | 07/05/2020


| A) Voting rights | Previous notification | After the transaction | ||||
|---|---|---|---|---|---|---|
| # of voting rights | # of voting rights | % of voting rights | ||||
| Holders of voting rights |
Linked to securities |
Not linked to the securities |
Linked to securities |
Not linked to the securities |
||
| S.R.I.W. | 715.491 | 1.88% | ||||
| TOTAL | 715.491 | 0 | 1.88% | 0,00% |
| B) Equivalent financial instruments |
After the transaction | ||||||
|---|---|---|---|---|---|---|---|
| Holder of equivalent financial instruments |
Type of financial instrument | Expiration date |
Exercise period or date |
# of voting rights that may be acquired if the instrument is exercised |
% of voting rights |
Settlement | |
| TOTAL | 0 | 0.00% |
| TOTAL (A & B) | # of voting rights |
%of voting rights |
|
|---|---|---|---|
| 715.491 | 1.88% |
• Full chain of controlled undertakings through which the holding is effectively held
S.R.I.W. is controlled by the Walloon Region.
Press release | 07/05/2020


IBA
Elodie Jaumain Paralegal +32 10 203 180 [email protected]
IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
Press release | 07/05/2020

Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.